Literature DB >> 16123173

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.

Kenneth E S Poole1, Rutger L van Bezooijen, Nigel Loveridge, Herman Hamersma, Socrates E Papapoulos, Clemens W Löwik, Jonathan Reeve.   

Abstract

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte-derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123173     DOI: 10.1096/fj.05-4221fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  301 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 2.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

3.  A model of osteoblast-osteocyte kinetics in the development of secondary osteons in rabbits.

Authors:  Ugo E Pazzaglia; Terenzio Congiu; Eleonora Franzetti; Marcella Marchese; Francesco Spagnuolo; Livio Di Mascio; Guido Zarattini
Journal:  J Anat       Date:  2012-02-13       Impact factor: 2.610

Review 4.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

5.  Identification of osteocyte-selective proteins.

Authors:  Dayong Guo; Andrew Keightley; Jill Guthrie; Patricia A Veno; Stephen E Harris; Lynda F Bonewald
Journal:  Proteomics       Date:  2010-10       Impact factor: 3.984

6.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

7.  Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

Authors:  W Yao; W Dai; L Jiang; E Y-A Lay; Z Zhong; R O Ritchie; X Li; H Ke; N E Lane
Journal:  Osteoporos Int       Date:  2015-09-18       Impact factor: 4.507

Review 8.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

9.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Authors:  Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation.

Authors:  Chenglin Mo; Sandra Romero-Suarez; Lynda Bonewald; Mark Johnson; Marco Brotto
Journal:  Recent Pat Biotechnol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.